{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.203","pValueComment":"A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.164","pValueComment":"A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.018","pValueComment":"A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.097","pValueComment":"A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.492","value":"4.48"},{"groupId":"OG001","spread":"9.152","value":"3.80"},{"groupId":"OG002","spread":"8.631","value":"4.41"},{"groupId":"OG003","spread":"9.971","value":"4.11"},{"groupId":"OG004","spread":"8.941","value":"2.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"97"}],"units":"Participants"}],"description":"The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (\"Not at all\") to 4 (\"Very much\") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Part A and had FACIT-F evaluated at Week 12. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}